{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:13:50Z","timestamp":1790802830268,"version":"4.1.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"AbbVie, Asahi-Kasei Pharma, AYUMI Pharmaceutical, Chugai Pharmaceutical, Eisai, Janssen Pharmaceutical, Ono Pharmaceutical, Sanofi, Teijin Healthcare and UCB Japan"},{"name":"information technology service company"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We evaluated real-world disease activity, treatment patterns and pregnancy outcomes in women with rheumatoid arthritis (RA) utilizing a multicentre Japanese cohort. Feasibility and impact of a treat-to-target (T2T) approach during pregnancy were also examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective observational study analysed 118 pregnancies in patients with RA from the multicentre ANSWER cohort (2013\u20132023) across eight Japanese academic institutions. Clinical characteristics, treatment regimens and RA Disease Activity Scores of 28 joints based on C-reactive protein (DAS28-CRP) were assessed at preconception, during each trimester and postpartum. Pregnancy and neonatal outcomes were analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 118 pregnancies, 92.8% achieved full-term deliveries (median birthweight: 2949\u2009g). Remission or low disease activity was maintained in \u223c85% of patients throughout pregnancy, with increased postpartum disease activity. Patients who continued biologic disease-modifying antirheumatic drugs (bDMARDs) during pregnancy (n\u2009=\u200935) exhibited significantly lower DAS28-CRP scores during the second and third trimesters compared with those who discontinued (n\u2009=\u200924) (P\u2009=\u20090.007 and P\u2009=\u20090.0002, respectively). Etanercept or certolizumab pegol use was associated with favourable disease control. Tocilizumab (n\u2009=\u20096) or abatacept (n\u2009=\u20092) was not associated with adverse maternal or neonatal outcomes. Glucocorticoid use was associated with increased disease activity. Salazosulfapyridine use correlated with increased birth weight (P\u2009=\u20090.003) and gestational age (P\u2009=\u20090.051).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>T2T management, including selective continuation of bDMARDs, was associated with favourable maternal disease control and reassuring pregnancy outcomes. Although the absence of long-term follow-up is a limitation, these findings provide real-world evidence supporting this approach. Larger prospective studies are required to confirm maternal and neonatal safety beyond the early postpartum.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf558","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T11:45:50Z","timestamp":1761133550000},"source":"Crossref","is-referenced-by-count":5,"title":["Effect of treat-to-target strategies on maternal and neonatal outcomes of rheumatoid arthritis: a multicentre real-world ANSWER cohort study"],"prefix":"10.1093","volume":"65","author":[{"given":"Yuri","family":"Hiramatsu","sequence":"first","affiliation":[{"name":"Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical and Pharmaceutical University , Takatsuki, Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2190-0780","authenticated-orcid":false,"given":"Takuya","family":"Kotani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical and Pharmaceutical University , Takatsuki, Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical and Pharmaceutical University , Takatsuki, Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1927-1295","authenticated-orcid":false,"given":"Ayaka","family":"Yoshikawa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical and Pharmaceutical University , Takatsuki, Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9241-060X","authenticated-orcid":false,"given":"Motomu","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Osaka Metropolitan University Hospital , Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Onishi","sequence":"additional","affiliation":[{"name":"Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University , Kyoto,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7896-3937","authenticated-orcid":false,"given":"Kouichi","family":"Murata","sequence":"additional","affiliation":[{"name":"Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University , Kyoto,","place":["Japan"]},{"name":"Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University , Kyoto,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University , Kyoto,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5981-4648","authenticated-orcid":false,"given":"Kosaku","family":"Murakami","sequence":"additional","affiliation":[{"name":"Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University , Kyoto,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Hirano","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Nishinomiya Municipal Central Hospital , Hyogo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6831-8205","authenticated-orcid":false,"given":"Yuichi","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University (FAU) , Erlangen, N\u00fcrnberg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2426-1024","authenticated-orcid":false,"given":"Kosuke","family":"Ebina","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Graduate School of Medicine, Osaka University , Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Sendo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine , Kobe,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7244-7715","authenticated-orcid":false,"given":"Yonsu","family":"Son","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Kansai Medical University , Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7299-2884","authenticated-orcid":false,"given":"Hideki","family":"Amuro","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Kansai Medical University , Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8000-3196","authenticated-orcid":false,"given":"Ryota","family":"Hara","sequence":"additional","affiliation":[{"name":"The Center for Rheumatic Diseases, Nara Medical University , Nara,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Katayama","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Connective Tissue Diseases, Osaka Red Cross Hospital , Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0810-4221","authenticated-orcid":false,"given":"Wataru","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Medical Information Management Department, Kurashiki Sweet Hospital , Okayama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0065-929X","authenticated-orcid":false,"given":"Tohru","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical and Pharmaceutical University , Takatsuki, Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"2026020205384619200_keaf558-B1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026020205384619200_keaf558-B2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"key":"2026020205384619200_keaf558-B3","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s10067-017-3962-5","article-title":"Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice","volume":"37","author":"Versteeg","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2026020205384619200_keaf558-B4","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"G\u00f6testam Skorpen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026020205384619200_keaf558-B5","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/rheumatology\/kev404","article-title":"BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding\u2014Part I: standard and biologic disease modifying antirheumatic drugs and corticosteroids","volume":"55","author":"Flint","year":"2016","journal-title":"Rheumatol (Oxford)"},{"key":"2026020205384619200_keaf558-B6","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1002\/art.24914","article-title":"Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study","volume":"60","author":"de Man","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2026020205384619200_keaf558-B7","first-page":"1314","article-title":"Disease activity and risk of preeclampsia in pregnant women with rheumatoid arthritis: a population-based study","volume":"66","author":"Vinet","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026020205384619200_keaf558-B8","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2020-219547","article-title":"Modern treatment approach results in low disease activity in 90% of pregnant rheumatoid arthritis patients: the PreCARA study","volume":"80","author":"Smeele","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026020205384619200_keaf558-B9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3899\/jrheum.180226","article-title":"Does rheumatoid arthritis really improve during pregnancy? A systematic review and metaanalysis","volume":"46","author":"Jethwa","year":"2019","journal-title":"J Rheumatol"},{"key":"2026020205384619200_keaf558-B10","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2026020205384619200_keaf558-B11","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/annrheumdis-2013-205079","article-title":"Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials","volume":"74","author":"Ward","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2026020205384619200_keaf558-B12","first-page":"194","article-title":"Low prevalence of flares in pregnant rheumatoid arthritis patients under adequate control with anti-TNF therapy: an observational study","volume":"16","author":"Bazzani","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"key":"2026020205384619200_keaf558-B13","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1080\/14397595.2020.1829342","article-title":"Simplified disease activity index and clinical disease activity index before and during pregnancy correlate with those at postpartum in patients with rheumatoid arthritis","volume":"31","author":"Nakamura","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2026020205384619200_keaf558-B14","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/acr.24130","article-title":"2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026020205384619200_keaf558-B15","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1093\/rheumatology\/keaa064","article-title":"Maternal and neonatal outcomes associated with biologic exposure before and during pregnancy in women with inflammatory systemic diseases: a systematic review and meta-analysis of observational studies","volume":"59","author":"Tsao","year":"2020","journal-title":"Rheumatol (Oxfordl)"},{"key":"2026020205384619200_keaf558-B16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","article-title":"Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study","volume":"77","author":"Mariette","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026020205384619200_keaf558-B17","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.semarthrit.2021.09.004","article-title":"A systematic review of the safety of non-TNF inhibitor biologic and targeted synthetic drugs in rheumatic disease in pregnancy","volume":"51","author":"Nguyen","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2026020205384619200_keaf558-B18","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1093\/rheumatology\/keac551","article-title":"British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids","volume":"62","author":"Russell","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205384619200_keaf558-B19","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1136\/annrheumdis-2021-221036","article-title":"Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy","volume":"81","author":"Ghalandari","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026020205384619200_keaf558-B20","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cgh.2012.11.011","article-title":"Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease","volume":"11","author":"Mahadevan","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026020205384619200_keaf558-B21","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1136\/ard-2022-222679","article-title":"Tumour necrosis factor inhibitor use during pregnancy is associated with increased birth weight of rheumatoid arthritis patients\u2019 offspring","volume":"81","author":"Smeele","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026020205384619200_keaf558-B22","doi-asserted-by":"crossref","first-page":"604866","DOI":"10.3389\/fphar.2020.604866","article-title":"IL-6 but not TNF\u03b1 levels are associated with time to pregnancy in female rheumatoid arthritis patients with a wish to conceive","volume":"11","author":"Bongenaar","year":"2020","journal-title":"Front Pharmacol"},{"key":"2026020205384619200_keaf558-B23","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1177\/1753495X20966094","article-title":"Tocilizumab drug levels during pregnancy and lactation: a woman who discontinued tocilizumab therapy until the end of the first trimester and resumed it after birth","volume":"14","author":"Saito","year":"2021","journal-title":"Obstet Med"},{"key":"2026020205384619200_keaf558-B24","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.semarthrit.2016.05.004","article-title":"Tocilizumab use in pregnancy: analysis of a global safety database including data from clinical trials and post-marketing data","volume":"46","author":"Hoeltzenbein","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2026020205384619200_keaf558-B25","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.semarthrit.2015.06.016","article-title":"Pregnancy outcomes following exposure to abatacept during pregnancy","volume":"45","author":"Kumar","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2026020205384619200_keaf558-B26","first-page":"351","article-title":"Pregnancy outcomes in subjects exposed to abatacept: a case series and literature review","volume":"45","author":"Clowse","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2026020205384619200_keaf558-B27","doi-asserted-by":"crossref","first-page":"887462","DOI":"10.3389\/fphar.2022.887462","article-title":"Stopping bDMARDs at the beginning of pregnancy is associated with disease flares and preterm delivery in women with rheumatoid arthritis","volume":"13","author":"Gerardi","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026020205384619200_keaf558-B28","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/art.24003","article-title":"Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study","volume":"59","author":"de Man","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2026020205384619200_keaf558-B29","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1038\/s41598-020-60451-2","article-title":"Peripartum issues in the inflammatory arthritis patient: a survey of the RAPPORT registry","volume":"10","author":"Dissanayake","year":"2020","journal-title":"Sci Rep"},{"key":"2026020205384619200_keaf558-B30","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1007\/s12325-020-01448-1","article-title":"Postnatal care of woman with rheumatic diseases","volume":"37","author":"Mouyis","year":"2020","journal-title":"Adv Ther"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf558\/64924000\/keaf558.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/1\/keaf558\/64924000\/keaf558.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/1\/keaf558\/64924000\/keaf558.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T10:38:54Z","timestamp":1770028734000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keaf558\/8300871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,8]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf558","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,10,24]]},"article-number":"keaf558"}}